

ASX: CVB

5 September 2024

ADJUSTMENT TO OPTION EXERCISE PRICE

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “**CurveBeam AI**” or the “**Company**”) today advises that in accordance with ASX Listing Rule 3.11.2, it has certain options on issue which, under ASX Listing Rule 6.22.2 and their terms, require their exercise price to be adjusted as a consequence of the pro-rata accelerated non-renounceable entitlement offer (“**ANREO**”) that closed on 22 August 2024.

ASX Listing Rule 6.22 confers on an option the right to a change to its exercise price if there is a pro-rata issue (except a bonus issue). The reduction in exercise price to be applied is outlined in the formula in ASX Listing Rule 6.22.2.

As a result of the recent ANREO, applying the formula in ASX Listing Rule 6.22.2 requires a reduction in the exercise price of the following options:

- 12,400,763 options issued concurrently with the issue of certain convertible notes in 2022 and prior to the Company’s IPO (**Noteholder Options**); and
- 16,448,315 options issued under the Company’s Omnibus Incentive Plan adopted by the Board on 11 May 2023 (**Plan Options**).

Effective 12 September 2024, the exercise price of the options will be adjusted in accordance with their terms and the ASX Listing Rules as follows:

Options on issue	Expiry Date	Original Price	Exercise Price	Adjusted Price	Exercise Price
12,400,763 Noteholder Options	21 August 2025	\$0.6720		\$0.66460429	
10,234,372 Plan Options	11 May 2029	\$0.5430		\$0.53560429	
360,000 Plan Options	11 May 2029	\$0.3250		\$0.31760429	
5,853,943 Plan Options	16 August 2029	\$0.8016		\$0.79420429	

Authorised for release by Greg Brown, the Chief Executive Officer.

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The



Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au